IL6ST and prostate carcinoma: The inflammatory microenvironments increased the abundance of TNFAIP8, SAT1, and IL6ST in various types of cancer including CRC.[42, 43] Their elevated expression levels are crucial for the proliferation and survival of CRC cells[39] and are associated with a poor prognosis of the patients.[43] Moreover, the IL6ST inhibitor bazedoxifene has shown antitumor efficacy in colon cancer,[41] prostate cancer,[44] and breast cancer,[45] suggesting that the TEX10‐NF‐κB‐IL6ST axis is a new target for the precision therapy in CRC.